News

Presentation Vaatdagen | Mar 18th 2019

Results of the First-In-Man clincial study will be presented by Daniel Eefting MD, Principal Investigator of the study

In December TripleMed moved to the new location on the Brightlands Chemelot Campus.

Next to additional office space , the new location contains a R&D lab and ISO7 clean production facilities

With this TripleMed is ready to expand their activities towards commercialization of AneuFix / AneuFill

End of January the METC approval for the type II endoelak study is expected to be received, after which the clinical study will start.

CA/EC requests for approvals in France, Germany and Belgium are ongoing

On November 23rd the preliminary results of the First-In-Man clinical study were presented at the Veith Congress by Prof. Jacobs.

TripleMed raises over €2 million for innovative treatment of aortic aneurysms